Media ReleasesArovella Therapeutics

View All Arovella Therapeutics News


SUDA Signs Additional Licence With Mitsubishi Tanabe


SUDA Pharmaceuticals Ltd (ASX: SUD), a leader inoro-mucosal drug delivery, today announces that it has entered into an exclusive licenseagreement with Mitsubishi Tanabe Pharma Korea Ltd (MTPK), a wholly owned subsidiaryof Mitsubishi Tanabe Pharma Corporation (MTPC) (“Agreement”).

For more information, please download the attached PDF
Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?